Social Media Ideas for Processa Pharmaceuticals

Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product

With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory...

<![CDATA[M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquire...

Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido

Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Wed, 07/29/2026 - 18:25 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Pa...

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

<![CDATA[Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Se...

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement ]]>

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

<![CDATA[M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Part...

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

<![CDATA[Eli Lilly to Acquire AtaiBeckley for $2.8 Billion ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Pasatru]]>

<![CDATA[M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Ent...

PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List

By Karla L. Palmer & Charles D. Snow & Mary Bass —

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals...

End-to-end: Curia drives supply and scale for steroid and hormonal therapies

Explore how Curia tackles steroid manufacturing complexity, from early development to scaled, end-to-end commercial supply. The post End-to-end: Curia drives supply and scale for s...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Simtriyo]]>

<![CDATA[Pharmaceutical Executive Daily: Pathos AI Enters Two lIcensing Deals]]>

<![CDATA[Amazon Pharmacy Launches GLP-1 Delivery Service ]]>